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Abstract
Background: Currently, broad empiric antimicrobial treatment including atypical coverage is
recommended for patients with mild to moderate community-acquired pneumonia (CAP).
Therefore, the relative impact of each atypical pathogen, particularly Mycoplasma pneumoniae
deserves renewed attention.
Methods: Based on prospective data from 4532 patients with CAP included in the German CAP-
Competence Network (CAPNETZ), we studied the incidence, clinical characteristics, and outcome
of patients with Mycoplasma pneumoniae pneumonia (MPP). The diagnosis of MPP was based on a
positive PCR from respiratory samples and/or a positive IgM-titer from an acute phase serum
sample.
Results: 307 patients (6.8%) had definite MPP (148 with positive PCR, 204 with positive IgM, 46
with positive PCR and IgM). Compared to patients with other definite and unknown etiologies,
patients with MPP were significantly younger (41 ± 16 versus 62 ± 17 and 61 ± 18 years), had fewer
co-morbidities, presented with a less severe disease, showed a lower inflammatory response in
terms of leukocyte counts (median 8850 versus 13200 and 11000 μL) and CRP values (60 versus
173 and 73 mg/L), and had better outcomes, including a shorter length of hospitalization (9 ± 5
versus 14 ± 11 and 12 ± 9 days), fewer patients requiring mechanical ventilation (0.3 versus 4.5 and
2.1%), and a minimal mortality (0.7 versus 8.7 and 6.5%).
Conclusion: In this large series of patients with definite MPP according to very strict criteria, MPP
appears as a condition with a high incidence, quite specific clinical presentation, and a largely benign
course. In view of a widely favorable clinical outcome, recent recommendations including regular
coverage of atypical pathogens in patients with mild to moderate CAP might be reconsidered for
patients in Germany as well as in other countries with comparable epidemiological settings.
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Background
Mycoplasma pneumoniae as an important pathogen of com-
munity-acquired pneumonia (CAP) is only rarely diag-
nosed in routine practice. This is explained by the many
limitations of paired serology which still is the applied
diagnostic tool in most cases. In several epidemiologic
studies of CAP, largely relying on paired serology, Myco-
plasma pneumoniae was identified in 5–15% of cases,
resulting in a second or third rank pathogen causing CAP
in most series [1,2]. Together with Legionella spp. and
Chlamydophila pneumoniae, these three pathogens are usu-
ally addressed as "atypical bacterial pathogens", and con-
sidered as prominent targets for broad spectrum
antimicrobial treatment including atypical coverage [3].
This approach is questionable for several reasons. First, it
may discourage clinical services to include microbial
investigations in their diagnostic work-up and thereby
promote the decline of any effort to design targeted anti-
microbial treatment. Second, relying on paired serology
for the diagnosis of MPP necessarily misses acute deaths
from pneumonia, and may thereby provide misleading
clinical descriptions of the disease and underestimate the
prognostic implications of this pathogen. Finally, lump-
ing together all three atypical pathogens throughout all
pneumonia severities at admission may heavily bias the
potential prognostic implications of the pathogens
included in this group, and thereby lead to recommenda-
tions of initial empiric antimicrobial treatment implying
frank overtreatment.
For these reasons, based on the large CAPNETZ database,
we aimed at identifying patients with CAP due to Myco-
plasma pneumoniae using a very strict methodology, in
order to revisit the epidemiology, clinical characteristics,
and the outcome of these patients. In addition, we
thought to reconsider the recommended diagnostic
approach to atypical pathogens on the background of our
findings.
Methods
Patient Population
A detailed description of the CAPNETZ methodology is
given elsewhere [4]. In short, the inclusion criteria for the
CAPNETZ study were age ≥ 18 years, the presence of a new
infiltrate in chest radiography, and at least one of the fol-
lowing criteria: history of fever (≥ 38.3°C), cough, pres-
ence of purulent sputum or focal chest signs on
auscultation. Patients who had been hospitalized during
28 days preceding the study, with severe immunosuppres-
sion or active tuberculosis were excluded.
The study was approved by the ethical review board, and
all patients included gave informed consent.
Data Collection
In this prospective study, all demographic, clinical and
diagnostic data of the patients were recorded using stand-
ardized web-based data sheets created by 2 mt® Ulm, Ger-
many. The study period comprised 55 months starting on
1st  June 2002 and ending 31st  December 2006, thus
including almost five autumn-winter seasons.
Microbiological Processing and Examination
Physicians were asked to provide a sputum sample from
all study patients. However, if the patient was not able to
produce a sputum sample, it was the physician's decision
to perform more invasive procedures. Methods applied
were described previously [5]. In short, sputum and/or
other respiratory secretions were immediately processed
in the participating local microbiological laboratories
according to the German Quality Standards in Clinical
Microbiology and Infectious Diseases MIQ [6]. The results
of virus testing are not included in this report.
Investigation for Mycoplasma pneumoniae and case 
definition for Mycoplasma pneumonia
Respiratory specimens and acute-phase serum were col-
lected, stored frozen for a maximum time period of 3
months and then sent to the central service unit in Ulm on
dry ice. After arrival at the central service unit complete-
ness of the number and kind of specimens was checked
and specimens were stored at -80°C. Both respiratory
specimen as well as sera were analysed retrospectively.
Physicians were not aware of the test results in time to
change therapy. The DNA from the clinical samples was
extracted by using the QIAamp DNA Mini Kit (Qiagen,
Hilden, Germany) according to the manufacturer's
instructions [7].
Detection of Mycoplasma DNA from respiratory samples
was performed in the Institute for Medical Microbiology
and Hygiene, Dresden, the German Consulting Labora-
tory for Mycoplasma pneumoniae by using a real-time PCR
targeting the inter-repetitive region of the P1 gene. We
used an antigen enriched with P1 (160 KD) mature
adhesin. The real-time PCR readily detects all subtypes
and variants of Mycoplasma pneumoniae with a detection
limit of approximately 10 genomic equivalents [8]. To
exclude an inhibition each sample was spiked with 1000
DNA copies and retested under the same conditions.
For the detection of Mycoplasma pneumoniae-specific IgG,
IgA or IgM antibodies the Virotech EIA (Genzyme Viro-
tech, Russelsheim, Germany) was used according to the
manufacturer's instructions. The EIA is based on a defined
antigen mix that includes the P1, P100, and P30 proteins.
In the present study, definite Mycoplasma pneumonia was
defined as: 1) a positive PCR based detection of Myco-BMC Infectious Diseases 2009, 9:62 http://www.biomedcentral.com/1471-2334/9/62
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plasma pneumoniae DNA in respiratory samples or 2) a
positive IgM test in the acute phase serum sample.
Statistical analysis
Comparisons between groups were performed by means
of the Chi square test for categorical variables or analysis
of variances (ANOVA) for continuous variables including
multiple comparisons. All analyses were performed with
SPSS software (SPSS 10.0, Chicago, IL). All tests of signif-
icance were 2-tailed, and alpha was set at 0.05. To correct
for multiple testing the Bonferroni correction was applied
to the variables presented in table 1 and the significance
level was consecutively set as p < .001.
Results
General characteristics of study population
Overall, 4532 patients with CAP from twelve clinical cent-
ers throughout Germany were included in our analysis.
The 2492 male and 2040 female patients had a mean age
of 60 ± 19 years. Sixty-five percent (n = 2922) of the
patients were hospitalized when first contacted for partic-
ipation in CAPNETZ. Co-morbidities were present in
2565 patients (57%). Thirty-one percent of the patients
were smokers. Fifty-six percent of all patients presented
with fever, 92% coughed, 73% had dyspnoea, and 8%
showed signs of confusion. 106 patients (2.3%) required
mechanical ventilation and 290 patients (6.4%) died (30
day mortality). The demographic and clinical data of the
patients are given in Table 1.
Diagnosis and epidemiology of Mycoplasma pneumonia
Respiratory samples were available from 1538 (33.6%) of
the patients (Table 2). 148 (9.6%) of patients with respi-
ratory samples had a positive Mycoplasma pneumoniae
PCR.
Acute serum samples were available in 4450 patients.
Altogether 204 (4.6%) patients had Mycoplasma pneumo-
niae-specific IgM antibodies in the acute phase serum
sample. 46 patients were positive in both PCR and IgM
antibody assay. Thus, 159 additional cases of Mycoplasma
pneumoniae  infection were identified by IgM antibody
detection.
Taken together, 307 patients (6.8%) were considered as
having definite Mycoplasma pneumonia (Table 2).
In support of our working definition, patients with a pos-
itive PCR from respiratory samples had almost identical
characteristics if compared to patients with a positive IgM
serum test, whilst patients with a positive IgA or IgG
serum test were older, predominantly men, more often
hospitalized, had higher CRB-65 scores and a fatality rate
of 7.5% and 6.3%, respectively (Table 3).
Clinical characteristics of patients with CAP caused by 
Mycoplasma pneumoniae
Patients with Mycoplasma pneumonia were significantly
younger than any other group of CAP patients with defi-
nite or unknown etiology in the study population (Figure
1) and clearly had fewer co-morbidities. The severity of
their pneumonia was much lower as reflected by a high
number of patients with low CRB-65 scores and a signifi-
cantly lower inflammatory response as reflected by
median leukocyte counts and CRP values on admission
(Table 1). There were no statistically significant differ-
ences for the variables smoker, fever, cough, new auscul-
tatory findings or chronic liver disease. In addition,
though not statistically significant only one patient had to
be mechanically ventilated and the length of hospitaliza-
tion was significantly lower. The fatality rate was very low
(0.7%) and significantly different if compared to the
groups with another definite or unknown etiology,
respectively.
Mixed infections of Mycoplasma pneumoniae with other
bacterial pathogens were present in 20 cases; in particular
Legionella spp. (n = 8), Streptococcus pneumoniae (n = 7),
Haemophilus influenzae (n = 3), and Staphylococcus aureus
(MSSA) (n = 2). None of the patients with mixed infection
died.
Of 307 patients with Mycoplasma pneumonia, 171 were
treated as outpatients and 136 were hospitalized. The
former group was even younger, had very mild pneumo-
nia, had fewer diabetic patients and a milder inflamma-
tory response. No outpatient died (Table 4).
Antimicrobial treatment and outcome of patients with 
Mycoplasma pneumonia
Detailed data concerning antimicrobial treatment were
available for 97% of all patients. The predominant classes
of antimicrobial agents administered were macrolides/
ketolides (37%) and fluoroquinolones (29%). Overall,
65% of patients with Mycoplasma  pneumonia had
received antimicrobial agents active against atypical bacte-
ria. There was a trend for patients with Mycoplasma pneu-
monia receiving more often antimicrobial agents covering
atypical bacteria than those with another bacterial or
without established etiology. There was no statistically
significant difference in outcome (p = .11) or length of
hospitalization (p = .057) between patients with Myco-
plasma pneumonia who received appropriate or inappro-
priate antibiotic therapy, respectively.
A 71-years old patient diagnosed by PCR died several
hours after he had been admitted to the hospital. The
cause of death was not established. An additional female
patient, aged 69 years, died after 10 days of hospitaliza-
tion. She suffered from COPD, was a heavy smoker andBMC Infectious Diseases 2009, 9:62 http://www.biomedcentral.com/1471-2334/9/62
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Table 1: Clinical characteristics and antimicrobial treatment of patients with Mycoplasma pneumoniae pneumonia (MPP), CAP due to 
other bacterial pathogens, and CAP with unknown etiology
Variable CAP due to other definite bacterial 
pathogens
n = 621
p1 MPP n = 307 p2 CAP with no known bacterial 
etiology n = 3604
Age (∅ ± SD) 61 ± 17 years .000 41 ± 16 years .000 61 ± 18 years
Male gender 58% .000 41% .000 56%
Outpatient/hospitalized 22%/78% .000 56%/44% .000 36%/64%
CRB 65 Score
0-1-2-3-4 (%)
33-46-16-4-1 .000 72-25-3-0.4-0 .000 39-43-15-2-0.4
Packyears(∅ ± SD) 32 ± 25 .000 15 ± 14 .000 29 ± 23
Pleural effusion 17% .000 6% .001 13%
Dyspnoea 80% .000 69% ns 72%
Pleural pain 47% .000 34% ns 42%
Confusion 11% .000 2% .001 8%
Oxygen requirement 57% .000 25% .000 41%
Malignancy 9% .000 2% .000 10%
Chronic respiratory disease 38% .000 20% .000 36%
Renal insufficiency 8% .001 2% .000 8%
Congestive heart failure 19% .000 4% .000 19%
Diabetes 20% .000 3% .000 16%
Respiratory sample obtained* 42% .000 58% .000 30%
Leucocytes (median)/μl 13 200 .000 8850 .000 11 000
CRP (median) mg/l 173 .000 60 .001 73
Duration of antibiotic therapy
(∅ ± SD)
13 ± 6 days .000 11 ± 4 days ns 11 ± 5 days
LOS in hospitalized patients
(∅ ± SD)
14 ± 11 days .000 9 ± 5 days .000 12 ± 9 days
Deaths within 30 days 54 (8.7%) .000 2 (0.7%) .000 234 (6.5%)
Patients with Mycoplasma pneumonia (MPP) were compared to patients with CAP due to other bacterial pathogens (p values marked as p1) and 
patients with CAP with unknown etiology (p values marked as p2), respectively. The significance level was set at < .001. (*) samples were available 
for standardized examination in the CAPNETZ central study unit. SD = standard deviation ns = not significantBMC Infectious Diseases 2009, 9:62 http://www.biomedcentral.com/1471-2334/9/62
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had to be mechanically ventilated. Both patients had not
received antibiotics active against atypical bacteria.
Discussion
The main findings of our study, based on very strict diag-
nostic criteria in a large population of patients with CAP,
can be summarized as follows: 1) Mycoplasma pneumoniae
is an important pathogen causing CAP 2) patients with
MPP are characterized by a quite specific clinical pattern,
including younger age, absent or limited co-morbidity,
limited inflammatory response, and usually presented
with a mild to moderate pneumonia; 3) as a consequence,
the majority of patients were treated as outpatients, hospi-
talized patients had a shorter length of stay, and mortality
was minimal; 4) patients with Mycoplasma  pneumonia
treated as outpatients had even milder pneumonia than
those hospitalized; 5) although there was a trend for
patients with Mycoplasma pneumonia receiving antimicro-
bial drugs active against atypical bacterial pathogens more
frequently than those with other or unknown etiologies,
the rate of discordant treatment remained high.
This study is unique for the strict criteria for the diagnosis
of  Mycoplasma  pneumonia and the large number of
patients identified by this diagnostic approach. It is also
unique for offering an identical extensive microbiological
workup for hospitalized as well as outpatients. The inci-
dence of Mycoplasma pneumoniae pneumonia was 6.7%,
which is at the lower range of previous figures reported in
recent large etiologic studies.
Previous series of patients with CAP due to Mycoplasma
pneumoniae have largely relied on serologic testing, either
using paired serum samples or including IgM and/or acute
IgG or IgA [9-14]. When designing our study it was
decided – due to feasibility – to collect only one acute
phase serum sample. This might be considered as a limi-
tation of our study.
When considering our study patients with M.pneumoniae
pneumonia we felt safe to designate patients with a posi-
tive PCR result from respiratory samples as a proven case
of M.pneumoniae infection. Due to the fact that in many
cases acute phase sera were available and serological tests
had been performed, we then had a closer look at our
serological test results to answer the question whether
patients with a positive IgM for M.pneumoniae  in their
acute phase serum might be considered as proven cases of
Table 2: Diagnosis of Mycoplasma pneumonia in 4532 adult patients with community acquired pneumonia
Method Samples tested Samples with positive test result
PCR from respiratory material 1538 148 (9,6%)
Sputum 1335 134 * (10,1%)
Broncho-alveolar lavage 67 8 (11,9%)
Others (Throat washings) 136 6** (4,4%)
IgM-Antibody EIA 4450 204 (4,6%)
IgA-Antibody EIA 4450 881 (19,8%)
IgG-Antibody EIA 4450 1042 (23,4%)
PCR from respiratory material + serum 1448
PCR positive + IgM-antibody positive 46 (3.2%)
PCR positive + IgA-antibody positive 55 (3.7%)
PCR positive + IgG-antibody positive 69 (4.7%)
PCR from respiratory material + serum 1448
PCR negative + IgM-antibody positive 31 (2.1%)
PCR negative + IgA-antibody positive 246 (17%)
PCR negative + IgG-antibody positive 272 (18.8%)
* 5 samples were inhibited
** 2 samples were inhibitedBMC Infectious Diseases 2009, 9:62 http://www.biomedcentral.com/1471-2334/9/62
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M.pneumoniae infection as well. In fact, the detection of
specific IgM antibodies is generally accepted as an indica-
tion of a recent infection. Two aspects persuaded us to fol-
low this hypothesis:
(i) IgM antibodies to M.pneumoniae are only very rarely
detected in the sera of healthy subjects. When evaluating
the Virotech kit used in our study in blood donors and
orthopaedic patients only 2 out of 602 patient samples
were IgM positive (0.3%), whereas IgA and IgG antibodies
were detected in a significant number of healthy persons
[[15], C. Lück, personal communication].
(ii) Patients with a positive PCR result had very similar
demographic and clinical characteristics if compared to
patients with IgM antibodies only. Especially if looking at
the initial CRB65 score, the proportion of patients requir-
ing mechanical ventilation and the outcome (Table 3), we
assumed it might be justified to regard PCR as well as IgM
only positive patients as an entity if discussing clinical
characteristics and management.
We used a commercially available test that uses specific
Mycoplasma pneumoniae proteins as antigens. Therefore, a
high specificity might be assumed and was demonstrated
in a recent publication [15]. The detection of Mycoplasma
pneumoniae  DNA has a high positive predictive value.
Albeit a persistence of Mycoplasma pneumoniae DNA after
infection or within the incubation time has been reported
it is generally accepted that such events are very rare
(<0,5%) [16,17].
In one third of our MPP patients we found concordant
positive PCR and positive IgM test results. The IgM EIA
used showed a moderate sensitivity in sera collected in the
acute phase [15]. Thus, it seems reasonable to assume that
some of the PCR positive patients might not yet have
developed IgM antibodies. On the other hand, PCR might
Table 3: Comparison of Mycoplasma pneumonia with positive PCR from respiratory samples to patients with positive serology results
Variables PCR positive
n = 148
Only IgM positive
n = 159
p-value1 Only IgA positive
n = 826
p-value2 Only IgG
positive
n = 973
p-value3
Age ≥ 50 years 23.6% 23.3% .841 67.6% .000 60.5% .000
Male gender 45% 38% .240 58% .003 54% .026
Smoker 29% 42% .017 37% .037 34% .243
Initial treatment setting
-outpatient 66% 46% .000 33% .000 39% .000
-hospitalized 34% 54% 67% 61%
Fever 68% 59% .081 55% .003 56% .004
Confusion 3% 2% .632 9% .013 8% .023
CRB 65 Score
0 74% 70% .499 41% .000 46% .000
1–2 22%/4% 29%/1% 42%/13% 38%/12%
3–4 0 1%/0 2%/1% 3%/1%
Mechanical ventilation 0 1 patient .332 23 patients .040 20 patients .078
Died within 30 days 1 patient
(0.7%)
1 patient
(0.6%)
.963 62 patients
(7.5%)
.002 61 patients
(6.3%)
.006
Patients with positive PCR were compared to IgM only (column p-values1) positive patients, to patients with only positive IgA (column p-values2) 
and patients with positive IgG only (column p-values3), respectively. Forty-six patients were positive in PCR and IgM, 55 patients were positive in 
PCR and IgA and 69 patients were positive in PCR as well as in IgG.BMC Infectious Diseases 2009, 9:62 http://www.biomedcentral.com/1471-2334/9/62
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have resulted false-negative due to the detection limit of
the PCR detection as well as the rapid elimination of Myc-
oplasma pneumoniae after the initiation of antimicrobial
treatment. In this context it should be noted that 27% of
our patients received antibiotic agents at the time of inclu-
sion into our study. The affection of antimicrobial treat-
ment on clinical presentation and PCR or IgM responses
in CAP caused by M.pneumoniae has never been studied to
our knowledge. Therefore, we ignore the true effect of this
confounder.
In contrast, clinical characteristics of patients with positive
IgA titers were similar to that of patients with other bacte-
rial and unknown etiologies but clearly different from the
population with positive PCR and/or IgM, indicating that
positive IgA titers represent persisting titers after infection
occurring at any time. Moreover, the high prevalence of
IgA antibodies (5–8%) found in blood donors and
patients without respiratory symptoms strongly indicates
a poor specificity. Therefore, IgA antibody detection is of
very limited use as a diagnostic tool of pneumonia due to
Mycoplasma pneumoniae.
Despite our different and strict diagnostic approach based
exclusively on real-time PCR in respiratory samples and
acute phase IgM, our data confirm previous findings of
MPP being associated with several peculiar clinical charac-
teristics. Apart from Chlamydophila pneumoniae, Myco-
plasma pneumoniae is the only bacterial respiratory
pathogen clearly occurring more frequently in younger
adults. In a large study on the etiology of CAP, Mycoplasma
pneumoniae was the only age-associated pathogen [18]. It
appears that it usually occurs before the forth decade. In
this age class, it has been shown that Mycoplasma pneumo-
niae can result as the most frequent pathogen even prior
to Streptococcus pneumoniae [9,19]. Probably as a conse-
quence, patients with Mycoplasma pneumoniae have con-
siderably fewer co-morbidities. The only concomitant
disease occurring with a frequency of more than 10% in
our MPP population was COPD.
Another important feature of MPP is its usually less severe
presentation, both in terms of clinical CRB-65 severity
scores as well as inflammatory response. None of the
severe complications of Mycoplasma pneumoniae reported
in the literature could be observed in our series [2],
although it cannot be definitely excluded that we missed
single cases with severe Mycoplasma  pneumonia. In
accordance with the regularly mild presentation of MPP,
and in line with several previous reports, more than half
of our patients were treated as outpatients, hospitalized
patients had a shorter length of hospitalization, and mor-
tality was very low [10-14]. Moreover, those treated as
outpatients were even younger and presented with a
milder pneumonia than those hospitalized (with 99%
having CRB-65 scores of less than 2).
Despite a trend for patients with MPP to receive more fre-
quently antimicrobial treatment covering atypical bacte-
rial pathogens, indicating that clinicians may have been
aware of a probable Mycoplasma pneumonia, the rate of
discordant treatment was high. Discordant treatment had
no discernable effect on outcomes such as length of stay
and mortality, indicating that MPP is usually a mild and
self-limiting disease. Of note, however, both patients who
died with MPP had received discordant treatment ini-
tially.
Our findings may have significant implications for future
recommendations of empiric antimicrobial treatment in
patients with CAP, particularly with respect to the need for
covering atypical pathogens. If we consider Legionella spp.,
Mycoplasma pneumoniae and Chlamydophila pneumoniae as
the three atypical bacterial pathogens treatable by antibac-
terial agents, it appears that only Legionella spp. are associ-
ated with a relevant mortality. In a recent series from our
group, we could show that Legionella spp. was found with
equal frequency in both ambulatory and hospitalized
Age distribution in 4527 patients with CAP Figure 1
Age distribution in 4527 patients with CAP. The data 
for five patients with CAP due to Chlamydophila pneumoniae 
and a mean age of 36.8 ± 6.8 years are not shown in this 
graph.BMC Infectious Diseases 2009, 9:62 http://www.biomedcentral.com/1471-2334/9/62
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patients. However, severity was low and mortality was
zero in ambulatory patients [5]. As a result, and in line
with a recent meta-analysis of outcomes in non-severe
CAP, atypical coverage does not seem to be relevant in
terms of prevention of mortality in outpatients with CAP
[20]. Following the definition of CAP used in our study
we would advocate that in Germany as well as in other
countries with comparable epidemiological settings a
dual treatment with coverage of atypical pathogens as
empirical standard therapy is not indicated for patients
with mild CAP. However, antibiotic pneumococcal cover-
age continues to be the main demand in the treatment of
this patient group.
Only recently, in a large study across four important world
regions, Arnold et al. found a lower mortality in hospital-
Table 4: Comparison of outpatients and hospitalized patients with Mycoplasma pneumoniae pneumonia
Variable Outpatients
N = 171
p value Hospitalized patients
N = 136
Age [∅ ± SD] 38 ± 13.1 .000 45 ± 18.4
Male gender 44% .320 38%
CRB – 65 score
0 79% .002 64%
1 – 2 20%/1% 30%/5%
3 – 4 01 %  -  0
Smoker 39% .185 32%
COPD 18% .239 23%
Diabetes 0.6% .013 5.1%
Malignancy 2% .946 2%
CRP median (mg/l) 33 .000 90
Leucocytes median (103/μl) 7900 .000 10300
Respiratory sample available 68% .000 46%
Serum available 98% .112 94%
Received antibiotic therapy active against atypical bacteria 64% .306 70%
Length of antimicrobial therapy (days) 10.6 ± 4.1 .026 11.6 ± 3.6
Dyspnoea 60% .000 80%
O 2 application 2% .000 55%
Died (30 day mortality) 0 .112 2 patientsBMC Infectious Diseases 2009, 9:62 http://www.biomedcentral.com/1471-2334/9/62
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ized patients receiving atypical coverage. As a result, and
referring to several other studies with similar findings,
they strongly recommended such coverage in all hospital-
ized patients [3,21,22]. In their study, the global inci-
dence of Legionella spp. was 5%, of Chlamydophila
pneumoniae  7%, and of Mycoplasma pneumoniae 12%.
However, the rate of patients discharged alive at 14 and 30
days was not different but appeared only significantly dif-
ferent when the total number of patients discharged alive
was considered, hinting at non-pneumonia-related rea-
sons for different outcomes. Several other reports also do
not support the conclusion of Arnold et al. [20,23-25].
Taking into account these reports and the present data,
increased mortality in hospitalized patients with CAP is
almost exclusively related to cases with moderate to severe
pneumonia caused by Legionella spp. Another concern
relates to mixed infections. In our series, the rate of mixed
infections was low (n = 20), with no associated mortality.
Most co-infections were caused by pneumococci and
Legionella spp. which may be detected using routine diag-
nostic methods according to current ATS/IDSA recom-
mendations [26]. Thus, a strategy of active search for
patients with Legionella spp. or, in cases of more severe
pneumonia, also for patients with Mycoplasma pneumoniae
and Chlamydophila pneumoniae should obviate the need of
regular atypical coverage in all hospitalized patients.
At present, we suggest that in hospitalized patients with
CAP coverage of atypical bacteria can be limited to
patients with severe CAP, those with confirmed legionel-
losis,  Chlamydophila pneumoniae pneumonia and those
with probable MPP, i.e. younger patients (age < 40 years)
with absent or mild co-morbidity and a mild clinical pres-
entation (CRB-65 < 2).
Conclusion
In conclusion, our study confirms previous reports about
characteristic patterns of CAP through Mycoplasma pneu-
moniae. However, realizing the minimal risk of adverse
outcomes associated with this condition, and having in
mind recent findings of our group on legionellosis, atypi-
cal coverage of all patients presenting with mild CAP as
defined in our study seems questionable. Instead, our
data provide important hints for strategies aimed at a
more judicious use of broad spectrum antimicrobial treat-
ment with atypical coverage.
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